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Objective: Comparison of recent national survey data
on prevalence, awareness, treatment and control of
hypertension in England, the USA and Canada, and
correlation of these parameters with each country
stroke and ischaemic heart disease (IHD) mortality.
Design: Non-institutionalised population surveys.
Setting and participants: England (2006 n=6873),
the USA (2007–2010 n=10 003) and Canada (2007–
2009 n=3485) aged 20–79 years.
Outcomes: Stroke and IHD mortality rates were
plotted against countries’ specific prevalence data.
Results: Mean systolic blood pressure (SBP) was
higher in England than in the USA and Canada in all
age–gender groups. Mean diastolic blood pressure
(DBP) was similar in the three countries before age 50
and then fell more rapidly in the USA, being the lowest
in the USA. Only 34% had a BP under 140/90 mm Hg
in England, compared with 50% in the USA and
66% in Canada. Prehypertension and stages 1 and 2
hypertension prevalence figures were the highest in
England. Hypertension prevalence (≥140 mm Hg SBP
and/or ≥90 mm Hg DBP) was lower in Canada
(19·5%) than in the USA (29%) and England (30%).
Hypertension awareness was higher in the USA (81%)
and Canada (83%) than in England (65%). England
also had lower levels of hypertension treatment (51%;
USA 74%; Canada 80%) and control (<140/90 mm Hg;
27%; the USA 53%; Canada 66%). Canada had the
lowest stroke and IHD mortality rates, England
the highest and the rates were inversely related to the
mean SBP in each country and strongly related to the
blood pressure indicators, the strongest relationship
being between low hypertension awareness and stroke
mortality.
Conclusions: While the current prevention efforts in
England should result in future-improved figures,
especially at younger ages, these data still show
important gaps in the management of hypertension in
these countries, with consequences on stroke and IHD
mortality.
INTRODUCTION
Increased blood pressure is the leading risk
factor for premature death, stroke and heart
disease worldwide.1 In the year 2000, the
world was estimated to have close to 1 billion
people with hypertension and predicted an
increase to 1.56 billion by 2025.2 The global
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economic burden of increased blood pressure was esti-
mated to consume US$370 billion worldwide and 10%
of healthcare expenditures.3 Usual blood pressure is
strongly and directly related to vascular and overall mor-
tality without evidence of a threshold down to at least
115/75 mm Hg,4 with small changes in blood pressure
resulting in substantial changes in vascular disease.5
On the basis of clinical and population research,
increased blood pressure, hypertension and
hypertension-related complications are largely prevent-
able. Lifestyle changes can lower blood pressure and
prevent hypertension while antihypertensive drug
therapy can effectively reduce the cardiovascular events
attributed to hypertension.1–6 Nevertheless, most people
with hypertension worldwide are not effectively treated
and controlled to the recommended blood pressure
targets.7 There are few national programmes to serve as
models for prevention and control of hypertension and
few countries have embarked on national hypertension
prevention and control programmes. The USA blood
pressure education programme was established in 19728
while Canada (2000) and England (2004) have recent
initiatives.9 10 This manuscript compares recent data on
the prevalence, awareness, treatment and control of
hypertension in England, the USA and Canada and cor-
relates these hypertension-related parameters in the
three countries with mortality from stroke and ischaemic
heart disease (IHD).
METHODS
Survey methods used in England, the USA and Canada
are summarised in table 1. Detailed methodology for each
survey is available elsewhere.11–13 Brieﬂy, each survey
is a representative sample of each country’s non-
institutionalised population and uses standardised proto-
cols and devices. While the England (2006) and Canada
(2007–2009) surveys used automatic oscillometric devices,
the USA (2007–2010) survey used mercury wall sphygmo-
manometer models. The number of blood pressure mea-
surements available for analysis varied by count of blood
pressure measures and survey protocols (table 1).
In these analyses, hypertension was deﬁned as a mean
systolic blood pressure (SBP) ≥ 140 mm Hg or a mean
diastolic blood pressure (DBP) ≥90 mm Hg or a
respondent self-report of medication to lower blood
pressure. Prehypertension (SBP 120–139 or DBP
80–89 mm Hg), stage 1 (SBP 140–159 mm Hg or DBP
Table 1 Survey methods, by country
Country Years of survey Sampling n
Age
range Response rate
England 2006 Multistage 6873 20–79 68% household response rate,
88% individual response rate in
co-operating households and
66% with nurse visit (examination
response rate).
Canada 2007–2009 Multistage 3485 20–79 Household response rate=70%
Individual response rate to the
household questionnaire=88%
Examination response rate=85%
USA 2007–2010 Multistage 10 003 20–79 Interview response rate=79%
Examination response rate=76%
93% of those examined had ≥2
blood pressure measurements




England Omron HEM 907 Nurse 3 Mean of second and third measures taken
1 min apart after 5 min rest
Canada Bp TRU BP-300* Health
measures
specialists
6 Average of last 5 of 6 measures taken 1 min
apart after a 5 min rest period
USA Calibrated V-Lok cuff, Latex
Inflation Bulb, Air-Flo Control
Valve. Baumanometer calibrated
mercury wall model.
Physician 3 Mean of second and third measurementS
taken 30 s apart after resting quietly in a
sitting position for 5 min†
All valid blood pressure readings excluding pregnant women.
*Bp TRU BP-100 used during home visits for respondents who were unable or unwilling to go at the mobile clinic.
†US NHANES survey protocol: After resting quietly in a sitting position for 5 min, three consecutive blood pressure readings were obtained.
If a blood pressure measurement was interrupted or incomplete, a fourth attempt could be made.
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90–99 mm Hg) and stage 2 (SBP ≥160 mm Hg or DBP
≥100 mm Hg) hypertension were deﬁned according to
the Seventh Report of the Joint National Committee on
the Prevention, Detection, Evaluation and Treatment of
High Blood Pressure ( JNC 7) deﬁnitions.6
Prevalence, awareness, treatment, control and aware-
ness of hypertension were deﬁned using commonly
recognised standards. Prevalence was deﬁned as SBP
≥140 or DBP ≥90 or currently taking medication to lower
their blood pressure. Awareness was deﬁned by self-report
and included, having been diagnosed as hypertensive by
a doctor or nurse, excluding women diagnosed during
pregnancy (England), medication to lower blood pres-
sure in the past month or reported high blood pressure
(Canada) or having been diagnosed as hypertensive by a
doctor or nurse, excluding women diagnosed during
pregnancy (USA). Treatment was deﬁned as taking medi-
cation to lower blood pressure, as recorded by the nurse
(England), or a self-report of taking medication to lower
blood pressure (Canada and the USA). Treated and con-
trolled was deﬁned as taking medication to lower blood
pressure and SBP<140 and DBP <90 mm Hg; treated and
uncontrolled a SBP ≥140 or DBP ≥90 mm Hg while on
medication to lower blood pressure. Aware, yet not
treated, was deﬁned by self-report and included having
been diagnosed as hypertensive by a doctor or nurse
(England)/healthcare provider (Canada and the USA)
and not taking medication to lower blood pressure.
Survey data were not age and sex standardised. They
represent the current country-speciﬁc ﬁgures and there-
fore correspond more precisely to each country’s crude
mortality rates for stroke and IHD. All prevalence ﬁgures
are weighted using survey weights to represent each coun-
try’s population. SEs were computed taking into account
each country’s sampling methodology.11–13 To be com-
parable across the three surveys, the analysis was
restricted to individuals aged 20–79 years and excluded
pregnant women. The Canadian Health Measures Survey
(CHMS) data analysis was performed using the SAS
Enterprise Guide (V.4.1, SAS Institute Inc, Cary, North
Carolina, USA, 2006). The Health Survey for England
(HSE) data analysis was performed using SPSS V.19. The
National Health and Nutrition Examination Survey
(NHANES) data analysis was performed using SAS V.9.2
and SAS-Callable SUDAAN V.10 (RTI International)), to
account for the complex sampling design.
The latest WHO country-speciﬁc mortality data avail-
able were from 2008 for Canada and the USA,14 and we
used the 2006 data for England.15 Crude mortality rates
per 100 000 were obtained for men and women for
stroke and ischaemic heart disease (IHD) and plotted
against country-speciﬁc prevalence data for hypertension
awareness, treatment and control.
RESULTS
The distribution of SBP and DBP by sex, age and
country shows an increase in SBP with age and an
increase, plateau and decrease in DBP with ageing
(ﬁgure 1; see online supplementary appendix 1 table).
SBP is higher in men than women in the younger age
groups and becomes higher in women than men after
age 60 years in Canada and age 70 years in England and
the USA. The mean SBP is overall higher in England
than in the USA and Canada in all age-gender groups.
DBP is similar in the three countries before age 50 and
then falls more rapidly in the USA while being lower
overall in men and women from the USA.
The distribution of measured blood pressure (includ-
ing treated individuals), by level, in table 2 reﬂects the
ﬁndings in ﬁgure 1. Only 34% of adults aged 20–79 years
would be classiﬁed as having a normal blood pressure
(<120/80 mm Hg) in England, compared with 50% in
the USA and 66% in Canada. Prehypertension and stages
1 and 2 hypertension prevalence ﬁgures are also much
higher in England than in the USA and Canada.
The prevalence of hypertension, and awareness, treat-
ment and control levels among those with hypertension
Figure 1 Distribution of systolic and diastolic blood pressure
by country, age and sex.
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are shown in table 3. The prevalence of hypertension is
lowest in Canada (19·5%) and higher in the USA (29%)
and England (30%). Hypertension awareness is close to
80% in the USA (81%) and Canada (83%) and lower in
England (65%). England also has lower levels of hyper-
tension treatment (England 51%; the USA 74%; Canada
80%) and control (England 27%; the USA 53%; Canada
66%). These patterns are similar in the different age
and sex subgroups (table 3). Among individuals treated
for hypertension (ie, taking medication to lower blood
pressure), the proportion being controlled is lowest in
England (53%), compared with 71% in the USA and
82% in Canada.
The mean SBP and DBP are provided in online
supplementary appendix 2 by the different prevalence
categories of table 3. The data are consistent with those
in the previous tables showing the highest SBP mean in
England in all categories. For DBP also, England has
higher means than the USA and Canada among all
hypertensives and the aware and treated categories.
At the time when these surveys were being conducted,
Canada had the lowest stroke and IHD mortality rates
while England had the highest. The rates of both out-
comes were inversely related to the mean SBP in each
country (ﬁgure 2). We found a strong relationship
between the selected blood pressure indicators and stroke
and IHD mortality, the strongest relationship being
between hypertension awareness and stroke mortality,
especially in women (ﬁgure 3). Stroke rates were higher in
women than men for any level of each of the BP indica-
tors, and the opposite was true for IHD (ﬁgures 2 and 3).
Discussion
Although all the three countries evaluated have had sub-
stantive improvement in most hypertension treatment
indicators over the past two decades,16–20 this study
found marked differences in hypertension prevalence,
awareness, treatment and control rates in England, the
USA and Canada. Canada has the lowest prevalence of
hypertension at 19% followed by England and the USA
at about 30% each. A previous study based on earlier
cycles of these surveys also found little difference in the
prevalence of hypertension between England and the
USA.21 The main determinants of hypertension are
known. These include poor dietary habits, excess
sodium intake, physical inactivity, obesity, excess alcohol
consumption, as well as age, gender, race and sociode-
mographic factors. The national differences in
Table 2 Distribution of measured blood pressure by level, sex, age and country
Total
Normal Prehypertension Stage 1 Stage 2
n Per cent SE n Per cent SE n Per cent SE n Per cent SE
ENGLAND
All 7382 2528 34.2 0.7 3242 43.9 0.7 1235 16.7 0.5 376 5.1 0.3
Sex
Males 3555 761 21.4 0.8 1903 53.5 0.9 709 19.9 0.7 182 5.1 0.4
Females 3826 1767 46.2 0.9 1339 35 0.9 526 13.7 0.6 195 5.1 0.4
Age
20–39 2618 1273 48.6 1.2 1115 42.6 1.1 210 8 0.6 20 0.8 0.2
40–59 2962 966 32.6 0.9 1360 45.9 0.9 482 16.3 0.7 155 5.2 0.4
60–79 1801 289 16.1 1 767 42.6 1.5 543 30.2 1.3 201 11.2 0.9
CANADA
All 3485 2214 66.1 1.7 955 27.2 1.4 259 5.4 0.3 57 1.3* 0.2*
Sex
Males 1649 951 60.6 2.4 538 32.9 2.2 140 5.9 0.5 20 0.7* 0.2*
Females 1836 1263 71.6 1.4 417 21.6 1.1 119 4.8 0.6 37 2.0* 0.5*
Age
20–39 1159 992 84.0 1.9 155 15.2 1.8 † † † † † †
40–59 1231 785 63.4 3.3 351 30.2 2.8 81 5.3 0.7 14 1.1* 0.3*
60–79 1095 437 39.4 2.0 449 42.9 2.2 168 13.8 1.1 41 3.9* 1.0*
USA
All 10 003 4663 50.3 0.8 3615 36.0 0.7 1296 11.0 0.4 429 2.7 0.2
Sex
Males 5033 1998 42.2 1.0 2109 42.7 1.0 713 12.2 0.6 213 2.8 0.3
Females 4970 2665 58.3 1.0 1506 29.3 0.8 583 9.7 0.5 216 2.7 0.2
Age
20–39 3394 2210 65.2 1.1 1007 29.7 1.1 148 4.4 0.4 29 0.7 0.1
40–59 3586 1608 46.5 1.3 1371 39.1 1.1 473 11.9 0.7 134 2.6 0.3
60–79 3023 845 30.8 1.3 1237 41.3 1.2 675 21.2 1.1 266 6.7 0.5
*Interpret with caution (coefficient of variation 16.6–33.3%).
†Too unreliable to be reported (coefficient of variation greater than 33.3%).
Normal: Systolic<120 and diastolic<80. Prehypertension: 120≤systolic<140 or 80≤diastolic<90. Stage 1: 140≤systolic<160 or
90≤diastolic<100. Stage 2: systolic≥160 or diastolic≥100. Regardless of medication use.
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prevalence are most likely related to differences in the
interaction between these determinants as well as differ-
ences in the clinical systems, community programmes
and environmental and policy supports for hypertension
prevention and management. Compared to the USA,
Canada has a lower rate of obesity, but to our knowledge
there has never been a comprehensive comparison of
the determinants of blood pressure using appropriately
adjusted data in these countries. A comprehensive com-
parison of the determinants of hypertension and the
policies that fail to address adverse differences in the
modiﬁable determinants would be an important next
step. This is also important since these data show an
important difference in the younger age groups between
England, Canada and the USA. Since blood pressure
tracks with age,22 efforts to inﬂuence the determinants
of hypertension are essential to reduce hypertension
prevalence in the older age groups. The recent decrease
in childhood obesity in England23 should be followed by
a reduction in blood pressure in the future surveys.
Our study has also found important differences in the
awareness, treatment and control of hypertension in the









Per cent SE Per cent SE Per cent SE Per cent SE Per cent SE Per cent SE
ENGLAND
All 30.0 0.7 65.3 1.2 51.3 1.2 27.3 1.1 23.9 0.9 14.1 0.8
Sex
Male 32.9 0.9 60.6 1.5 45.1 1.6 23.9 1.4 21.2 1.2 15.5 1.1
Female 27.3 0.8 70.7 1.5 58.2 1.6 31.1 1.6 27 1.4 12.5 1.1
Age
20–39 9.3 0.7 35 3.1 10.6 2.1 5 1.4 5.6 1.7 24.4 2.9
40–59 27.9 0.8 59.3 1.7 40.8 1.8 23.1 1.5 17.7 1.2 18.5 1.3
60–80 63.7 1.3 76.1 1.6 67.4 1.7 35.1 1.8 32.3 1.6 8.7 0.9
CANADA
All 19.5 0.6 83.4 1.8 79.9 2.0 65.8 2.0 14.0 2.0 3.5* 0.9*
Sex
Male 19.7 1.1 80.4 2.2 76.5 2.1 66.8 3.0 9.7* 2.0* 3.9* 0.9*
Female 19.3 0.6 86.5 2.0 83.3 2.4 64.9 2.8 18.4* 3.2* † †
Age
20–39 2.0* 0.6* 64.4 9.8 58.4* 10.3* 56.8* 10.6* † † † †
40–59 18.4 1.5 80.4 2.7 73.4 3.7 65.4 3.8 8.0* 1.8* 7.0* 2.3*
60–79 53.2 2.4 86.7 1.8 85.7 2.1 66.8 1.8 19.0 2.6 † †
USA
All 29.1 0.8 81.1 1.0 74.0 1.1 52.8 1.0 21.2 0.7 7.0 0.7
Sex
Male 29.4 1 77.7 1.4 69.1 1.5 48.7 1.6 20.3 1.1 8.6 1
Female 28.8 0.9 84.6 1.2 79.1 1.4 57 1.5 22.1 1 5.5 0.7
Age
20–39 7.7 0.6 61.1 4.6 47.2 4.0 35.0 3.6 12.2 2.4 13.9 2.5
40–59 31.1 1.2 82.4 1.4 73.1 1.8 53.5 1.7 19.6 1.3 9.4 1.0
60–79 63.6 1.3 84.2 1.3 80.9 1.4 56.1 1.5 24.8 0.9 3.3 0.6
Hypertension: systolic pressure≥140 or diastolic pressure≥90 or currently taking blood pressure-lowering medication.
Awareness, treatment and control were assessed among those with hypertension.
Aware: Self-report of having been diagnosed as hypertensive by a doctor or nurse, excluding women diagnosed during pregnancy (England);
Self-reported BP medication use in the past month or self-reported high-blood pressure (Canada); Self-report of having been diagnosed as
hypertensive by a doctor or nurse, excluding women diagnosed during pregnancy (USA).
Treated: Taking medication to lower blood pressure recorded by the nurse (England); taking medication to lower blood pressure, self-report
(Canada, USA).
Treated and controlled: taking medication to lower blood pressure and DBP <90 and SBP<140 mm Hg.
Treated and uncontrolled: taking medication to lower blood pressure and DBP >=90 or SBP >=140 mm Hg.
Aware, not treated: Self-reported of having been diagnosed as hypertensive by a doctor or nurse, not taking medication to lower blood
pressure (ENGLAND); Self-reported of having been told by a healthcare provider that they have high blood pressure, not taking medication to
lower blood pressure (Canada); Self-reported of having been told by a healthcare provider that they have high blood pressure, not taking
medication to lower blood pressure (USA).
Unaware: No self-report of having been diagnosed as hypertensive by a doctor or nurse (ENGLAND); no self-report of having been told that
they have high-blood pressure and no self-report of BP medication use in the past month (Canada); no self-report of having been told that
they have high-blood pressure (USA).
*Interpret with caution (coefficient of variation 16.6–33.3%).
†Too unreliable to be reported (coefficient of variation greater than 33.3%).
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three countries. England, the USA and Canada all have
developed differing approaches to improve hypertension
treatment and control. In the USA, several diverse
approaches have been taken.6 8 24 Historically, the USA
has had one of the world’s highest rates of hypertension
awareness, treatment and control and has also seen
improvements in these indicators with intensiﬁed
efforts18; however, despite broad clinical and community
efforts, over half of the adults with hypertension are
uncontrolled based on the current guidelines.19 Recent
national activities and recommendations are staged to
positively impact hypertension estimates.25–29
Importantly, we also found national-level differences
in mortality rates from stroke and IHD, which paralleled
the differences in hypertension awareness, treatment
and control between these three countries. Stroke and
IHD mortality were strongly inversely correlated with
mean SBP in each country.
Efforts in England have included episodic national
hypertension recommendations developed by the British
Hypertension Society (BHS—a non-governmental organ-
isation of specialists and researchers) with the recom-
mendations recently being developed by a governmental
organisation in collaboration with the BHS.30
Figure 2 Stroke and ischaemic heart disease (IHD) mortality* by country mean SBP.
Figure 3 Stroke and IHD mortality by country prevalence of hypertension awareness, treatment and control.
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Implementation programmes have included an extensive
public programme to educate people on the risks of salt
for hypertension31 and also an extensive government
programme to make bonus payments to general practi-
tioners for achieving benchmarks for hypertension
care32—although the efﬁcacy of payment for perform-
ance for improving hypertension control has been
questioned.33
In 2000, Canada launched an annually updated hyper-
tension recommendations programme (Canadian
Hypertension Education Programme (CHEP)).9 In
2006, the programme was assisted by an extensive initia-
tive to inform the public about hypertension and the
health risks and opportunities to reduce dietary salt.34
The introduction of CHEP in Canada is temporally
related to improvements in management patterns and
has also been temporally associated with reduced cardio-
vascular disease in Canada.35
It is difﬁcult to assess how much the different national
approaches to hypertension detection and management
impact on the differences observed in our study. British
Guidelines in place in 200610 36 and since30 do not rec-
ommend the routine use of antihypertensive treatment
for those with a SBP >140 and/or DBP >90 mm Hg;
rather, they do so only if such people have an estimated
10 year CV risk of >20%. Consequently, treatment rates
and control rates might be expected to be lower in
England than in the USA and Canada. Furthermore, in
England, the National Institute for Health and Clinical
Excellence’s Quality and Outcomes Framework, which
includes measures used in the calculation of provider
reimbursement, included a higher blood pressure target
(<150/90) during the period of data used for these ana-
lyses. This will be lowered (to <140/90) in 2013/2014 to
align with the national guidelines. In addition to the new
National Institute for Health and Clinical Excellence
guidelines,30 the national salt reduction programme in
England would be expected to result in further reduc-
tions in the prevalence of hypertension and improvement
in hypertension treatment indicators in recent and future
years as Canadian and Finnish data suggest.37 38
There are several potential limitations to our current
analyses. In addition to the low response rates and
hence small numbers in some strata, each country uses
different methodology to assess blood pressure and rela-
tively small differences in blood pressure can impact the
hypertension indicators. In particular, Canada has
adopted the use of a fully automated blood pressure
device that operates in the absence of an observer and
averages the last ﬁve of six blood pressure readings. The
Canadian method reduces the inﬂuence of the observer
(white coat effect) on blood pressure and results in a
slightly lower average blood pressure than a single aus-
cultatory blood pressure reading. Nevertheless, using an
algorithm to adjust the data in the Canadian survey39 to
represent a single manual reading results in little
change in the major hypertension indicators as the dif-
ference in methods at the therapeutic cut point of 140/
90 mm Hg is relatively small but might reduce the differ-
ences between the USA and Canada. The close relation-
ship between stroke mortality and hypertension
prevalence and hypertension indicators suggests that the
blood pressure and hypertension differences seen in this
study are real and biologically important. We acknow-
ledge the limitation of using three points for our mortal-
ity graphs, which require a high level of correlation to
be statistically signiﬁcant.
We did not use age-adjusted or gender-adjusted data
from the different countries. The lack of adjustment was
intended so that the hypertension risk factors could be
directly compared to stroke mortality for each country.
In addition, in a separate analysis, comparison of
age-adjusted data to a common standard population
showed very little difference with the current ﬁgures. We
were not able to obtain more recent common mortality
data than 2008 for all countries. There is some overlap
between the timing of the US and Canadian surveys, but
the English survey was conducted more than 1 year
earlier. Management of hypertension in England is quite
likely to have improved since 2006. Increased blood pres-
sure and hypertension represent major global threats to
population health, with stroke and IHD being the most
closely related adverse outcomes.4 Interventions to lower
the average population blood pressure and interventions
to identify and control blood pressure in those with
hypertension are critical to prevent blood pressure-
related complications.2–6 Nevertheless, the hypertension
control rates are low even in developed countries and
most countries do not have formal programmes to
control hypertension.40 Further, population surveys indi-
cate that approximately 29% of men and 25% of women
have uncontrolled hypertension with increasing
numbers of hypertension cases globally due to popula-
tion growth and ageing.41 Hence, countries worldwide
should consider introducing and evaluating coordinated
programmes to improve the prevention, detection,
awareness, treatment and control of hypertension, and
our data suggest that the more assertive approach appar-
ent in North America is associated with large beneﬁts in
terms of reduced cardiovascular mortality. A greater
focus on prevention of high blood pressure in the
younger age groups is also necessary.
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